Korro Bio, Inc. (KRRO) SEC Filings & Earnings Calls
EquiReason read 21 Korro Bio, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-22 — Korro Bio announced preclinical results for KRRO-111, a development candidate for Alpha-1 Antitrypsin Deficiency. Preclinical data is early-stage; no efficacy or safety endpoints r.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 176.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
22 Oct 20268-K · 8.01Korro Bio announced preclinical results for KRRO-111, a development candidate for Alpha-1 Antitrypsin Deficiency. Preclinical data is early-stage; no efficacy or safety endpoints reported, so polarity is neutral with moderate magnitude.open
Risks flagged
Preclinical stage; no clinical data to assess efficacy or safety.
“Preclinical results only; no human trial data.”
5 Oct 20268-K · 8.01Dosed first cohort in Phase 1/2 ANCHOR trial of KRRO-121 for urea cycle disorders and hepatic encephalopathy. No data yet.open
Risks flagged
Early-stage clinical trial; no data yet; inherent development risk.
“Phase 1/2 trial; first cohort dosed.”
19 Aug 20268-K · 8.01Announced submission to Australian ethics committee to initiate first-in-human Phase 1/2 trial for KRRO-121 (RNA editing oligonucleotide) for urea cycle disorders. No data yet; trial initiation milestone.open
Risks flagged
First-in-human clinical trial risks
“risks of conducting a first-in-human clinical trial; challenges with addressing any regulatory concerns necessary to proceed with enrollment and dosing” · word for word
6 Aug 20268-K · 1.01, 2.02, 3.02Korro Bio entered an exchange agreement with VenRock to surrender 1M shares and issue pre-funded warrants for 1M shares, increasing potential dilution. Cash runway into H2 2028.share dilutionopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q2-2026 | $138M | |
| Shares outstanding · Q2-2026 | $14M |
Risks flagged
Pre-funded warrants represent potential dilution of ~30% of current shares.
“Unexercised pre-funded warrants to acquire 4,148,836 shares of its common stock.” · word for word
Clinical-stage biotech with no approved products; regulatory and clinical risk.
“KRRO-121 remains on track to commence first-in-human clinical trial in second half of 2026; regulatory approval needed.”
6 Aug 202610-QKorro Bio reported Q2 2026 net loss improved to $18.9M from $25.8M YoY, with cash runway into H2 2028.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q2-2026 | $-19M | -27% y/y |
| Cash, cash equivalents and marketable securities · Q2-2026 | $138M | |
| Accumulated deficit · Q2-2026 | $422M | |
| Research and development expenses · Q2-2026 | $14M | -33% y/y |
| General and administrative expenses · Q2-2026 | $7M | -11% y/y |
| Net cash used in operating activities · H1-2026 | $33M | -24% y/y |
Risks flagged
No revenue from product sales
“We have not generated any revenue from product sales, and do not expect to generate any revenue from the sale of products in the near future.” · word for word
Dependence on additional funding
“We will need substantial additional funding to support our continuing operations and pursue our development and growth strategy.” · word for word
Clinical and regulatory uncertainty
“The scientific evidence to support the feasibility of developing our development candidates using our RNA editing technology is both preliminary and limited.” · word for word
Collaboration pause risk
“In November 2025, we agreed to a 12-month pause on our collaboration with Novo Nordisk.” · word for word
4 Aug 2026SC 13D/AAtlas Venture funds filed an amendment to Schedule 13D disclosing aggregate 5.9% beneficial ownership in Korro Bio, with no stated activist intent.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage (Atlas Venture Fund XI) · 2026-08-04 | 4.9% | |
| Beneficial ownership percentage (Atlas Venture Opportunity Fund II) · 2026-08-04 | 1.0% | |
| Aggregate beneficial ownership · 2026-08-04 | 5.9% |
4 Aug 2026SC 13D/AAtlas Venture funds filed an amendment to Schedule 13D disclosing aggregate 5.9% beneficial ownership in Korro Bio, with no stated activist intent.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage (Atlas Venture Fund XI) · 2026-08-04 | 4.9% | |
| Beneficial ownership percentage (Atlas Venture Opportunity Fund II) · 2026-08-04 | 1.0% | |
| Aggregate beneficial ownership · 2026-08-04 | 5.9% |
19 May 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen
Risks flagged
Early-stage pipeline addition; clinical and regulatory risk remains.
“Program is in development; no clinical data disclosed.”
7 May 20268-K · 2.02Korro Bio reported Q1 2026 financial results with net loss of $19.6M vs $23.4M prior year; cash $157.1M; no revenue; R&D expenses decreased; provided corporate update on pipeline progress.earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q1-2026 | $157M | +84% y/y |
| Net loss · Q1-2026 | $-20M | -16% y/y |
| Research and Development Expenses · Q1-2026 | $13M | -35% y/y |
| General and Administrative Expenses · Q1-2026 | $8M | -4% y/y |
Risks flagged
No revenue from collaboration due to pause with Novo Nordisk
“Collaboration revenue paused for 12 months since November 2025.”
Pre-revenue biotech with significant cash burn
“Net loss of $19.6M in Q1 2026; cash runway into H2 2028.”
7 May 202610-QNet loss $-20M; Accumulated deficit $-404M; Cash, cash equivalents and marketable securities $157Mopen
Figures in the filing · each found in the filing text
| Net loss · Q1-2026 | $-20M | |
| Accumulated deficit · 2026-03-31 | $-404M | |
| Cash, cash equivalents and marketable securities · 2026-03-31 | $157M | |
| Research and development expenses · Q1-2026 | $13M | -34% y/y |
| General and administrative expenses · Q1-2026 | $7M | -4% y/y |
| Collaboration revenue · Q1-2026 | $0.00 | -100% y/y |
| Operating cash flow · Q1-2026 | $-16M |
Risks flagged
Pre-revenue biotech with no approved products
“We do not have any development candidates approved for sale and have not generated any revenue from product sales.” · word for word
Novo Nordisk collaboration paused
“In November 2025, we agreed to a 12-month pause on such collaboration with Novo Nordisk, accordingly, we do not expect to recognize any material collaboration revenue under such agreement during the 12-month hold period.” · word for word
KRRO-110 trial terminated
“a $5.4 million decrease in KRRO-110 external expenses primarily due to the termination of the Phase 1/2a REWRITE clinical trial during the first quarter of 2026.” · word for word
12 Mar 20268-K · 2.02Cash, cash equivalents and marketable securities $85M (-48% y/y); Collaboration Revenue $6M (+178% y/y); Research and Development Expenses $66M (+3% y/y)earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · FY2025 | $85M | -48% y/y |
| Collaboration Revenue · FY2025 | $6M | +178% y/y |
| Research and Development Expenses · FY2025 | $66M | +3% y/y |
Risks flagged
Cash burn remains high; reliance on private placement for runway.
“Cash decreased from $163.1M to $85.2M; $85M private placement extends runway into H2 2028.”
12 Mar 202610-KEmployees 58; long-lived asset impairment charge $31Mopen
Figures in the filing · each found in the filing text
| employees · FY2025 | 58 | |
| long-lived asset impairment charge · FY2025 | $31M |
9 Mar 20268-K · 1.01, 2.02, 3.02, 7.01Korro Bio announced an oversubscribed $85M PIPE financing led by Venrock Healthcare Capital Partners, extending cash runway into H2 2028.open
Figures in the filing · each found in the filing text
| cash, cash equivalents and marketable securities · Q4-2025 | $85M |
Risks flagged
Dilution from PIPE issuance of 4.5M shares and 3.1M pre-funded warrants.
“Korro is selling an aggregate of (i) 4,501,928 shares of its common stock at a purchase price of $11.11 per share and (ii) pre-funded warrants to purchase 3,148,836 shares of its common stock at a price of $11.109 per pre-funded warrant.” · word for word
18 Dec 20258-K · 5.02Annual base salary $425,000.00; cash bonus $100,000.00; restricted stock units 41,902open
Figures in the filing · each found in the filing text
| annual base salary · 2025 | $425000.00 | |
| cash bonus · 2025 | $100000.00 | |
| restricted stock units · 2025 | 41,902 |
Risks flagged
No material risk; compensation changes are standard retention tools.
12 Nov 20258-K · 1.01, 2.02, 2.05, 5.02Cash, cash equivalents and marketable securities $102M; Workforce reduction 34; One-time restructuring charges $2Mopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q3-2025 | $103M | |
| Workforce reduction · Q4-2025 | 34.0% | |
| One-time restructuring charges · Q4-2025 | $2M |
Risks flagged
Lead asset KRRO-110 missed protein level targets in clinical trial
“KRRO-110 did not reach projected levels of functional protein following a single administration” · word for word
Key partnership with Novo Nordisk paused for 12 months
“pause the collaboration and license agreement for 12 months” · word for word
Workforce reduction of 34% indicates severe cost-cutting
“workforce reduction of approximately 34%” · word for word
12 Nov 202510-QKorro Bio reported Q3 2025 results with lead candidate KRRO-110 failing to meet efficacy threshold, workforce reductions, and Novo Nordisk collaboration pause.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q3-2025 | $-67M | |
| Accumulated deficit · 2025-09-30 | $334M | |
| Cash, cash equivalents and marketable securities · 2025-09-30 | $103M | |
| Collaboration revenue · Q3-2025 | $5M | |
| Research and development expenses · Q3-2025 | $55M | |
| General and administrative expenses · Q3-2025 | $22M |
Risks flagged
Clinical trial failure risk
“KRRO-110 did not reach projected levels of functional protein following a single administration as of the data cutoff date.” · word for word
Cash runway risk
“We have incurred significant operating losses since inception. Our net losses were $67.2 million and $62.4 million for the nine months ended September 30, 2025 and 2024, respectively.” · word for word
Collaboration dependency risk
“In November 2025, we agreed to a 12 month pause on such collaboration with Novo Nordisk, accordingly, we do not expect to recognize any material collaboration revenue under such agreement during the 12-month hold period.” · word for word
Korro Bio, Inc. — questions
- What did Korro Bio, Inc. file recently?
- 21 SEC filings in the last 12 months. Latest: 8-K on 2026-10-22 — Korro Bio announced preclinical results for KRRO-111, a development candidate for Alpha-1 Antitrypsin Deficiency. Preclinical data is early-stage; no efficacy or safety endpoints reported, so polarity is neutral with moderate magnitude.
Every figure on this page comes from Korro Bio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.